Green Cross Health Ltd · NZX:GXH
Green Cross Health — Shareholder Meeting (July 2025)
31 slides from Green Cross Health's shareholder meeting presentation, Jul 31, 2025
Slide 1: Annual Shareholders' Meeting
Annual Shareholders’ Meeting 31 July 2025 GXH Annual Shareholders’ Presentation 31 July 2025 Pg 1
Slide 2: Kim Ellis, Independent Chair
Kim Ellis Independent Chair GXH Annual Shareholders’ Presentation 31 July 2025 Pg 2
Slide 3: Questions Process
Questions Process • Any eligible shareholder/proxy attending the meeting remotely is able to ask a question. • Select the Q&A tab and type your question into the box at the bottom of the screen and press ‘Send’. *Note: If you have signed in as a guest, you will not be able to ask questions or vote a
Slide 4: Introductions
Carolyn Steele John Bolland Ken Orr Board Independent Director Non-Executive Director Independent Director Members Introductions Craig Brockliss Peter Merton Andrew Bagnall Non-Executive Director Non-Executive Director Non-Executive Director Management Rachael Newfield Kalpana Goundar Group CEO CFO/
Slide 5: Agenda
Agenda Chair’s address Group CEO’s address Resolutions and voting General Q&A GXH Annual Shareholders’ Presentation 31 July 2025 Pg 5
Slide 6: Rachael Newfield, Group CEO's Address
Rachael Newfield Group CEO’s Address GXH Annual Shareholders’ Presentation 31 July 2025 Pg 6
Slide 7: Group Revenue and Operating Profit
Group Revenue and Operating Profit GXHGXH Operating Revenue Operating RevenueFrom FromContinuing Continuing Operations ($m) GXH Operating Profit From Continuing Operations ($m) Operations ($m) 523.8 48.5 503.9 34.3 38.7 493.6 31.8 478.1 FY22 FY22 FY23 FY23 FY24 FY24 FY25 FY25 FY22 FY22 FY23 FY23 FY2
Slide 8: Group NPAT, EPS & Dividend
Group NPAT, EPS & Dividend GXH NPAT Attributable to Shareholders* ($m) Dividends Per Share (cps) 34.0 20.2 15.0 16.0 6.5 7.0 12.0 4.5 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 Based on dividends paid during the financial year GXH NPAT Attributable to Shareholders* (cps) • Net Profit After Tax Attribut
Slide 9: Working Capital and Operating Cashflow
Working Capital and Operating Cashflow GXH Gearing Ratio (debt / debt + equity) GXH Operating Cash Flow ($m) 17.3% 65.8 45.9 46.0 52.6 12.3% 10.4% 11.9% FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 • Gearing ratio of 11.9% as at 31 March 2025 • Operating Cash Flow of $52.6m • Undrawn debt facilities of $
Slide 10: Divisional Performance & Plans
Divisional Performance & Plans GXH Annual Shareholders’ Presentation 31 July 2025 Pg 10
Slide 11: Pharmacy Performance
Pharmacy Performance Pharmacy Operating Revenue ($m) 370.4 • Revenue up 2% to $370.4m with strong 367.1 363.6 performance in dispensary, partially offset by 360.4 retail decline FY22 FY22 FY23 FY23 FY24 FY24 FY25 FY25 • Operating Profit up to $21.5m driven by top Pharmacy Operating Profit ($m) line
Slide 12: Care & Advice Health Hub
11 core clinical Care & Advice Health Hub services available in all Care & Advice Health Hubs 77,000 service Launch of the Care & Advice Health Hub within Unichem & Life pharmacies bookings made online positioned to support New Zealand’s growing demand for essential health services 41% increase in n
Slide 13: Investment in Beauty
Investment in Beauty Modernising the Life brand instore experience with the launch of the first ‘Beauty by Life’ concept at the Life Newmarket store Targeting further stores to be upgraded by the end of the year Enhancing the beauty and wellness product offering by introducing new ranges and product
Slide 14: Improving Customer Journey
Improving Customer Journey Targeted offers for products and services through the Living Rewards Living Rewards membership grew to over programme 2.09 million members, with members spending 50% more than non-members Enhancing the product range with Website upgraded to new and exclusive improve functi
Slide 15: Pharmacy Future Focus
Pharmacy Future Focus Clinical Retail Customer Network scale Cost services disciplines experience & leadership focus Expand clinical Workforce Differentiated brands Improving customer Leveraging our trusted services through Care productivity, margin and products with accessibility & brands & advocat
Slide 16: Medical Performance
Medical Performance Medical Operating Revenue ($m) Revenue up 9% to $153.4m primarily 133.2 140.3 153.4 due to full year impact of FY24 111.0 acquisitions and one FY25 acquisition FY22 FY23 FY24 FY25 Operating Profit up to $19.5m driven FY22 FY23 FY24 FY25 by acquisition and operational improvement
Slide 17: Focus on Operational Performance
Focus on Operational Performance Operational Efficiency 80% 16% 70% 14% • Focus on operational efficiency, including 60% 12% through utilisation of technology, has 50% 10% improved employee costs to 72% of Revenue Cost % EBIT % 40% 8% • Continuing to advocate for improved funding arrangements to ens
Slide 18: Investment and Innovation
Investment and Innovation • Baymed and Kerikeri practices underwent major refurbishments adding capacity to care for more patients, in an upgraded clinical environment • The Doctors rebranding programme continued with 45 centres now operating under the brand • Over 120,000 registered users on The Do
Slide 19: Medical Future Focus
Medical Future Focus Innovative Direct Operations Cost Technology improvement & margin care model funding High quality patient care Calling for improved Utilising data and Continuous Workforce delivered through a funding arrangements systems to increase improvement in productivity & margin team-base
Slide 20: Company Overview
Company Overview Our Purpose: Working together to support healthier communities. We are passionately committed to the health and wellness of New Zealand, and to providing the best support, GXH Annual Shareholders’ Presentation 31 July 2025 Pg 20 care and advice to our communities. This is our promis
Slide 21: Questions
Questions GXH Annual Shareholders’ Presentation 31 July 2025 Pg 21
Slide 22: Resolutions & Voting
Resolutions & Voting GXH Annual Shareholders’ Presentation 31 July 2025 Pg 22
Slide 23: Voting
Voting • Resolutions will be put forward once voting is declared open by the Chair. Once the voting has opened, the resolution and voting options will appear. • To vote, simply select your voting direction from the options shown on screen. You can vote for all resolutions at once, or by each resolut
Slide 24: Resolutions
Resolutions 1 Resolution 1: Re-election of Kim Ellis 2 Resolution 2: Re-election of John Bolland 3 Resolution 3: Re-election of Craig Brockliss 4 Resolution 4: Directors’ fee pool 5 Resolution 5: Fix the remuneration of the Auditor for the ensuing year GXH Annual Shareholders’ Presentation 31 July 2
Slide 25: Resolution 1: Re-election of Kim Ellis
Resolution 1 Re-election That Kim Ellis be re-elected as a Director of the Company Kim Ellis Independent Chair GXH Annual Shareholders’ Presentation 31 July 2025 Pg 25
Slide 26: Resolution 2: Re-election of John Bolland
Resolution 2 Re-election That John Bolland be re-elected as a Director of the Company John Bolland Non-Executive Director GXH Annual Shareholders’ Presentation 31 July 2025 Pg 26
Slide 27: Resolution 3: Re-election of Craig Brockliss
Resolution 3 Re-election That Craig Brockliss be re-elected as a Director of the Company Craig Brockliss Non-Executive Director GXH Annual Shareholders’ Presentation 31 July 2025 Pg 27
Slide 28: Resolution 4: Directors' fee pool
Resolution 4 That the Directors’ fee pool be increased by $100,000 from $500,000 to $600,000 per annum with effect from 1 April 2025 GXH Annual Shareholders’ Presentation 31 July 2025 Pg 28
Slide 29: Resolution 5: Auditor remuneration
Resolution 5 To authorise the Directors to fix the remuneration of the Auditor for the ensuing year GXH Annual Shareholders’ Presentation 31 July 2025 Pg 29
Slide 30: Questions
Questions GXH Annual Shareholders’ Presentation 31 July 2025 Pg 30
Slide 31: Disclaimer
Disclaimer The information in this presentation was prepared by Green Cross Health Limited (GXH) with due care and attention. However, the information is supplied in summary form and is therefore not necessarily complete, and no representation is made as to the accuracy, completeness or reliability